It is worth setting expectations up front
Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK Lymphadenopathy is not listed in the Summary of Product Characteristics or reported in SURPASS or SURMOUNT clinical trials Common Mounjaro side effects are predominantly gastrointestinal, including nausea, vomiting, diarrhoea, and reduced appetite Lymph node swelling during treatment may result from infections, vaccinations, local inflammation, or other unrelated conditions Persistent, enlarging, or hard lymph nodes require GP evaluation to exclude serious underlying causes including malignancy Report any suspected adverse effects through the MHRA Yellow Card Scheme for ongoing pharmacovigilance monitoring Table of Contents Understanding Mounjaro and Its Common Side Effects Mounjaro (tirzepatide) is a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus
(2021), New England Journal of Medicine, 384(11), 989-1002
For patients with complex medical histories, comorbidities, or anxiety about managing injectable medications without hands-on support, it probably does
While other GHS compounds like GHRP-2 and GHRP-6 are effective, they are often criticized for their lack of specificity
How does PlexusDx tirzepatide compare to Fridays
